Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClotTM rapid serum blood collection tube technology in Japan.

Q-Sera Pty Ltd, an Australian company, announced that Terumo Corporation has launched VenoJect II RAPClot evacuated blood collection tubes in Japan. This advanced tube technology aims to enhance laboratory management and improve patient outcomes.

This launch marks the first major innovation in Japan's blood collection tube market, aiming to reduce turnaround time from sample collection to serum analysis and to improve laboratory management compared to existing technologies.

According to Towards Healthcare, the activated clotting time testing market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 561.08 million in 2026 to approximately USD 1112.29 million by 2035, representing a compound annual growth rate (CAGR) of 7.9% from 2026 to 2035. Growth is driven by the increasing importance of activated clotting time testing in modern healthcare diagnostics, ensuring patient safety and optimal treatment outcomes. Technology advancements include point-of-care devices and automated systems, which enhance the efficiency and accuracy of testing.

CEO of Q-Sera, Michael Grant, said, “Q-Sera is pleased to announce the first launch of its patented technology by Terumo Corporation in the Japanese market. Japan has a history of innovation in blood collection tubes, with Terumo Corporation a leader in this sector, and together we look forward to launching this next-generation tube technology to benefit patients and the health care system.

About Q-Sera

It is the start-up company that is commercialising intellectual property developed at The University of Queensland (UQ) and licensed to Q-Sera by UniQuest, UQ’s commercialisation company. Involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to produce high-quality serum for biochemical analysis.

About Terumo

Terumo Corporation has the exclusive rights to use Q-Sera’s technology to manufacture and market its VenoJect II RAPClot tubes in Japan. This has also involved the scaling-up of Q-Sera’s recombinant protein, ecarin (RAPClot), which can now be manufactured at commercial scale to a high-quality level using standard biopharmaceutical processes.

Director of Essential Medical Products, Terumo Wataru Ninokura, said VenoJect II RAPClot tubes are a true innovation in blood collection tubes and have the potential to dramatically improve issues such as coagulation time, heparinized blood, and fibrin strands in tests with serum. It will be a great pleasure for us to be able to directly contribute to improving the accuracy of diagnosis.

A recent report by Towards Healthcare highlights that the Activated Clotting Time testing market is witnessing growth as it plays a vital role in personalized patient care and safety during invasive procedures, making it a critical component of modern healthcare diagnostics propelled by stringent regulatory standards and the need for reliable, real-time diagnostics.

North America is dominated by high adoption rates of advanced diagnostic technologies and stringent regulatory standards. North America is a key market for ACT testing solutions. Asia-Pacific is emerging as a high-growth zone; this region is witnessing the rapid adoption of automation-driven ACT testing platforms, supported by government initiatives to improve healthcare infrastructure.